Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671304 | 0.77 | LTA4H (0.50) | HDAC6HDAC1LTA4HADORA2APDE4A | |
| SCHEMBL820304 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1LTA4H | |
| SCHEMBL48336 | 0.77 | ADORA2A (0.47) | HDAC6HDAC1LTA4HNPC1HPGD | |
| SCHEMBL7109676 | 0.75 | LTA4H (0.48) | HDAC6HDAC1LTA4HADORA2APDE4A | |
| SCHEMBL338773 | 0.75 | HDAC6 (0.52) | HDAC6HDAC1LTA4HADORA2B | |
| SCHEMBL11066170 | 0.74 | ADORA2A (0.50) | HDAC6HDAC1LTA4HADORA2BNPC1 | |
| SCHEMBL1079073 | 0.72 | FDPS (0.50) | HDAC6HDAC1LTA4HADORA2BNPC1 | |
| SCHEMBL5635371 | 0.72 | LTA4H (0.49) | HDAC6HDAC1LTA4HADORA2BADORA2A | |
| SCHEMBL13044929 | 0.72 | HDAC6 (0.47) | HDAC6HDAC1LTA4HNPC1RAB9A | |
| SCHEMBL8875192 | 0.72 | LTA4H (0.45) | LTA4HADORA2BNPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163484-A1 | METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES | UNIVERSITÉ GRENOBLE ALPES (FR) | 2021-06-03 | — | — | US | disclosed |
| EP-3619211-A1 | METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES | Université Grenoble Alpes (FR) | 2020-03-11 | — | — | EP | disclosed |
| CN-110582496-A | Methods for synthesizing variously substituted purines | 格勒诺布尔-阿尔卑斯大学 | 2019-12-17 | — | — | CN | disclosed |
| WO-2018203099-A1 | METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES | UNIVERSITE GRENOBLE ALPES (FR) | 2018-11-08 | — | — | WO | disclosed |
| US-9572891-B2 | Oligonucleotide conjugates | GERON CORPORATION (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150374841-A1 | Oligonucleotide Conjugates | GERON CORPORATION | 2015-12-31 | — | — | US | disclosed |
| US-9072790-B2 | Oligonucleotide conjugates | GERON CORPORATION (US) | 2015-07-07 | — | — | US | disclosed |
| EP-1543021-B1 | OLIGONUCLEOTIDE CONJUGATES | GERON CORP (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130253042-A1 | Oligonucleotide Conjugates | GERON CORPORATION (US) | 2013-09-26 | — | — | US | disclosed |
| US-8501897-B2 | Method for producing liquid-crystalline polyester | SUMITOMO CHEMICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8492500-B2 | Method for producing liquid-crystalline polyester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8440635-B2 | Oligonucleotide conjugates | GERON CORPORATION (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130030142-A1 | METHOD FOR PRODUCING LIQUID-CRYSTALLINE POLYESTER | SUMITOMO CHEMICAL COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20130030141-A1 | METHOD FOR PRODUCING LIQUID-CRYSTALLINE POLYESTER | SUMITOMO CHEMICAL COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20100016416-A1 | Oligonucleotide Conjugates | GERON CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-7563618-B2 | Oligonucleotide conjugates | GERON CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060141523-A1 | Integrated method for PCR cleanup and oligonucleotide removal | APPLERA CORPORATION (US) | 2006-06-29 | — | — | US | disclosed |
| US-20040009602-A1 | DNA modifying molecules and methods of use thereof | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2004-01-15 | — | — | US | disclosed |
| US-20030138814-A1 | Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) | GERON CORPORATION | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163484-A1 | METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES | PNP, UMPS, NUDT1 | HDAC6 4462/4885HDAC1 4460/4885LTA4H 1690/4885 |
| US-20150374841-A1 | Oligonucleotide Conjugates | TERT, RNGTT, TRDMT1 | HDAC6 1179/4885HDAC1 1374/4885LTA4H 2859/4885 |
| US-20130253042-A1 | Oligonucleotide Conjugates | TERT, RNGTT, TRDMT1 | HDAC6 1179/4885HDAC1 1374/4885LTA4H 2859/4885 |
| US-20030138814-A1 | Comprises RNA and nucleobase/fluorophore for inhibition of human telomerase activity (inhibits growth of cancerous cells) | TERT, RNGTT, DUT | HDAC6 1082/4885HDAC1 807/4885LTA4H 3110/4885 |
| US-20100016416-A1 | Oligonucleotide Conjugates | TERT, RNGTT, TRDMT1 | HDAC6 1179/4885HDAC1 1374/4885LTA4H 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.